

BAB VII

Daftar Pustaka

1. Rosenbloom AL. Physiology of growth. *Ann Nestle*. 2008;65(3):97–108.
2. Esparza SD, Sakamoto KM. Topics in Pediatric Leukemia – Acute Lymphoblastic Leukemia. *Medscape Gen Med* [Internet]. 2005 [cited 2021 Oct 25];7(1):23. Available from: [/pmc/articles/PMC1681386/](#)
3. Perdana AB, Saputra F, Aisyi M. Update on Diagnosis of Childhood Acute Lymphoblastic Leukemia (ALL) in Indonesia. *Indones J Cancer* [Internet]. 2020 Dec 28 [cited 2021 Oct 25];14(4):115–6. Available from: <https://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/818>
4. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. *J Clin Oncol*. 2011 Feb 10;29(5):532–43.
5. Puckett Y, Chan O. Acute Lymphocytic Leukemia. *StatPearls* [Internet]. 2021 Jun 29 [cited 2021 Oct 25]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459149/>
6. Hatta Y. [Acute lymphoblastic leukemia]. *Rinsho Ketsueki*. 2014;55(2):185–90.
7. Tebbi CK. Etiology of acute leukemia: A review. *Cancers (Basel)*. 2021;13(9):1–19.
8. Stieglitz E, Loh ML. Genetic predispositions to childhood leukemia. *Ther Adv Hematol*. 2013 Aug;4(4):270–90.
9. Heuser M, Thol F, Ganser A. Klonale Hämatopoese von unbestimmtem Potenzial. *Dtsch Arztebl Int*. 2016;113(18):317–22.
10. Mullighan CG, Collins-Underwood JR, Phillips LAA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. *Nat Genet*. 2009 Nov;41(11):1243–6.
11. J. G. Bloom's syndrome. *XX. The first 100 cancers*. 1997;100–6.
12. Bielora B, Fisher T, Waldman D, Lerenthal Y, Nissenkorn A TT et al. A. lymphoblastic leukemia in early childhood as the presenting sign of

- ataxiatangiectasia variant. *Pediatr Hematol Oncol*. 2013;574–82.
13. Sehgal S, Mujtaba S, Gupta D, Aggarwal R, Marwaha RK. High incidence of Epstein Barr virus infection in childhood acute lymphocytic leukemia: a preliminary study. *Indian J Pathol Microbiol*. 2010;53(1):63–7.
 14. Geriniere L, Bastion Y, Dumontet C, Salles G, Espinouse D CB. Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients. 1994;437–40.
 15. Basu R, Kopchick JJ. The effects of growth hormone on therapy resistance in cancer. *Cancer Drug Resist [Internet]*. 2019 Sep 19 [cited 2022 Aug 22];2(3):827–46. Available from: <https://cdrjournal.com/article/view/3124>
 16. Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. *Mediterr J Hematol Infect Dis*. 2014;6(1):e2014073.
 17. Bogin B. Human Growth and Development. *Basics Hum Evol*. 2015;(December 2015):285–93.
 18. Rosenbloom AL. Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options? *J Pediatr*. 2007 Jan;150(1):7–11.
 19. KL J. Smith's Recognizable Patterns of Human Malformation. 2005;
 20. Smith DW, Truog W, Rogers JE, Greitzer LJ, Skinner AL, McCann JJ, et al. Shifting linear growth during infancy: illustration of genetic factors in growth from fetal life through infancy. *J Pediatr*. 1976 Aug;89(2):225–30.
 21. Smith DW. *Growth and Its Disorders*. 1977;
 22. ROOT A. Overgrowth syndromes: evaluation and management of the child with excessive linear growth. *Pediatr Endocrinol*. 2007;(5):163–94.
 23. Habicht JP, Martorell R, Yarbrough C, Malina RM, Klein RE. Height and weight standards for preschool children. How relevant are ethnic differences in growth potential? *Lancet (London, England)*. 1974 Apr;1(7858):611–4.
 24. Berkey CS, Ware JH, Speizer FE, Ferris BGJ. Passive smoking and height growth of preadolescent children. *Int J Epidemiol*. 1984 Dec;13(4):454–8.
 25. de Onis M, Branca F. Childhood stunting: a global perspective. *Matern Child Nutr*. 2016 May;12 Suppl 1(Suppl 1):12–26.
 26. Shalet SM. Irradiation-induced growth failure. *Clin Endocrinol Metab*. 1986 Aug;15(3):591–606.

27. Casanueva FF. Physiology of Growth Hormone Secretion and Action. *Endocrinol Metab Clin North Am.* 1992 Sep 1;21(3):483–517.
28. Bozzola M, Meazza C. Growth Velocity Curves : What They Are and How to Use Them Metadata of the chapter that will be visualized online. 2012;(July 2016).
29. Rixe SNKRTO. Skeel’s Handbook of Cancer Therapy. 9th ed.
30. Colvin M. Cancer Medicine. 2003;(6th Edition).
31. Muggia FM, Green MD. New anthracycline antitumor antibiotics. *Crit Rev Oncol Hematol.* 1991;11(1):43–64.
32. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. *Pharmacol Ther.* 2000;87(2–3):227–53.
33. Wellstein A, Giaccone G, Atkins MB SE. Textbook of pharmacology and therapeutics. 2020;(Md):12–3.
34. Altun İ, Sonkaya A. The Most Common Side Effects Experienced by Patients Were Receiving First Cycle of Chemotherapy. *Iran J Public Health.* 2018 Aug;47(8):1218–9.
35. Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). *Hematology Am Soc Hematol Educ Program.* 2009;371–81.
36. Ramirez LY, Huestis SE, Yap TY, Zyzanski S, Drotar D, Kodish E. Potential chemotherapy side effects: What do oncologists tell parents? *Pediatr Blood Cancer.* 2009;52(4):497–502.
37. Halton JM, Atkinson SA, Fraher L, Webber C, Gill GJ, Dawson S, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. *J Bone Miner Res.* 1996;11(11):1774–83.
38. Olney RC. Regulation of bone mass by growth hormone. *Med Pediatr Oncol.* 2003;41(3):228–34.
39. Gutch M, Philip R, Philip R, Toms A, Saran S, Gupta K. Skeletal manifestations of juvenile hypothyroidism and the impact of treatment on skeletal system. *Indian J Endocrinol Metab.* 2013;17(7):181.